Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck & Co. lowered the top end of its full-year sales forecast after demand for its HPV vaccine fell for a second straight quarter in China.

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni-2 trial. The study ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Keytruda racked up a stunning $25 billion in ... Despite having no products to sell, Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni ...